Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model

An effective therapy regimen for relapsed/refractory high-risk neuroblastoma (NB) includes the anti-GD2 monoclonal antibody, dinutuximab, in combination with temozolomide and irinotecan, supporting a role for chemo-immunotherapy in NB. γδ T cells are an attractive anti-tumor immunotherapy because of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zoine, Jaquelyn T., Knight, Kristopher A., Fleischer, Lauren C., Sutton, Kathryn S., Goldsmith, Kelly C., Doering, Christopher B., Spencer, H. Trent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682349/
https://www.ncbi.nlm.nih.gov/pubmed/31413905
http://dx.doi.org/10.1080/2162402X.2019.1593804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682349/
https://www.ncbi.nlm.nih.gov/pubmed/31413905
http://dx.doi.org/10.1080/2162402X.2019.1593804

Ejemplares similares